X

Trial Profile

A Phase II Study of Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Raltitrexed (Primary)
Indications Colorectal cancer
Focus Therapeutic Use

Most Recent Events

13 Sep 2022 Preliminary results (n=94) presented at the 47th European Society for Medical Oncology Congress
27 Aug 2021 Planned End Date changed from 15 Feb 2020 to 15 Feb 2023.
27 Aug 2021 Planned primary completion date changed from 15 Aug 2018 to 15 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com